Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497067 · ClinicalTrials.gov registry record · NA
Long Term Safety Protocol for the AcrySof CACHET Phakic Lens
A NA study, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 657
- Enrollment target
NCT01497067: Completed NA study, sponsored by Alcon Research.
NCT01497067 is a NA study that has completed, run by Alcon Research. The registered enrollment target is 657 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01497067, a NA study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 657 participants
- Enrollment target
Study Summary
The purpose of this long term safety study is to estimate the annualized endothelial cell loss (ECL) rate (for up to 10 years following date of implantation) of subjects previously implanted with the ACRYSOF CACHET Phakic Intraocular Lens (L-series) from precursor clinical studies C-02-23, C-02-40, C-03-21 and C-05-57.
Primary Outcome
A microscope was used to photograph corneal endothelial cells (cells on the back of the cornea). Three images at the center of the cornea were obtained and sent to a central reading center for analysis. All recorded data from images were used in the analysis. A higher value for density represents a healthier cornea.
Interventions
- DEVICE ACRYSOF CACHET Phakic Lens (L-series)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 657 participants |
| Start Date | 2011-11-21 |
| Est. Completion | 2018-06-15 |
| Phase | NA |
What the finished NCT01497067 record still lists
NCT01497067 is an interventional study that assigns participants to a tested intervention. The registered 657 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which ACRYSOF CACHET Phakic Lens (L-series) is the first listed.
NCT01497067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01497067 about?
NCT01497067 is a clinical study titled "Long Term Safety Protocol for the AcrySof CACHET Phakic Lens". The purpose of this long term safety study is to estimate the annualized endothelial cell loss (ECL) rate (for up to 10 years following date of implantation) of subjects previously implanted with the ACRYSOF CACHET Phakic Intraocular Lens (L-series) from precursor clinical studies C-02-23, C-02-40, ...
What is the current status of trial NCT01497067?
This trial is currently completed. It is a NA study. The enrollment target is 657 participants. The study started on 2011-11-21. Estimated completion is 2018-06-15.
What interventions are being tested in trial NCT01497067?
The interventions under investigation include: ACRYSOF CACHET Phakic Lens (L-series) (DEVICE).
Who is sponsoring clinical trial NCT01497067?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01497067's enrollment target sits among peer trials
657 156th of 2000 higher than 1,845 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI